These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14556684)

  • 21. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
    J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
    Enting RH; Demopoulos A; DeAngelis LM; Abrey LE
    Neurology; 2004 Sep; 63(5):901-3. PubMed ID: 15365145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen.
    Drapkin R; Di Bella NJ; Faragher DC; Harden E; Matei C; Hyman W; Mirabel M; Boehm KA; Asmar L
    Clin Lymphoma; 2003 Dec; 4(3):169-75. PubMed ID: 14715099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remarkable response to rituximab in a patient with atypical CD20(++) mantle cell lymphoma of the bone marrow leading to severe pancytopenia.
    Seggewiss R; Ho AD; Kraemer A
    Ann Hematol; 2004 May; 83(5):316-8. PubMed ID: 15064861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab monotherapy in nodular lymphocyte-predominant Hodgkin's disease.
    Boulanger E; Meignin V; Leverger G; Solal-Céligny P
    Ann Oncol; 2003 Jan; 14(1):171. PubMed ID: 12488312
    [No Abstract]   [Full Text] [Related]  

  • 27. Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma.
    Galán L; Sánchez AC; Cantos B; Provencio M
    Clin Transl Oncol; 2010 May; 12(5):384-6. PubMed ID: 20466624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab.
    Czuczman MS; Grillo-López AJ; Alkuzweny B; Weaver R; Larocca A; McLaughlin P
    Leuk Lymphoma; 2006 Sep; 47(9):1830-40. PubMed ID: 17064996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibodies for the treatment of diffuse large cell lymphoma.
    Blum KA; Bartlett NL
    Semin Oncol; 2003 Aug; 30(4):448-56. PubMed ID: 12939713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection.
    Spina M; Sparano JA; Jaeger U; Rossi G; Tirelli U
    AIDS; 2003 Jan; 17(1):137-8. PubMed ID: 12478085
    [No Abstract]   [Full Text] [Related]  

  • 31. Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non-Hodgkin's lymphoma: a phase II study.
    Bremer K
    Anticancer Drugs; 2003 Nov; 14(10):809-15. PubMed ID: 14597875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
    Bienert M; Reisinger I; Srock S; Humplik BI; Reim C; Kroessin T; Avril N; Pezzutto A; Munz DL
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1225-33. PubMed ID: 15937686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy and survival status of retuximab-NCE regimen treatment in patients with relapsed or refractory B cell non-Hodgkin's lymphoma].
    Hou Y; Wang HQ; Fu K; Liu XM; Zhang HL; Qian ZZ; Qiu LH; Li W; Zhou SY; Li LF; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):306-10. PubMed ID: 22781046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
    Hao LC; Zhang LZ
    Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
    [No Abstract]   [Full Text] [Related]  

  • 35. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response.
    Gluck WL; Hurst D; Yuen A; Levine AM; Dayton MA; Gockerman JP; Lucas J; Denis-Mize K; Tong B; Navis D; Difrancesco A; Milan S; Wilson SE; Wolin M
    Clin Cancer Res; 2004 Apr; 10(7):2253-64. PubMed ID: 15073100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
    Maeda LS; Advani RH
    Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria.
    Ha CS; Kavadi V; Dimopoulos MA; Hagemeister FB; Osborne BM; Fuller LM; Smith TL; Hess MA; McLaughlin PW; Cabanillas FF; Cox JD
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):329-34. PubMed ID: 10030257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.